📬 GI Cancer Intelligence Digest — Week 2026-W36
FDA approved daraxonrasib for previously treated metastatic pancreatic adenocarcinoma and zanidatamab-based regimens for first-line HER2-positive gastroesophageal adenocarcinoma, while NEST, STAR-TREC, EMERALD-3, TALENTACE and TALENTOP reported in print.
⚡ TL;DR
📄 Publications
- Atezolizumab with or without tiragolumab in unresectable esophageal squamous cell carcinoma following definitive concurrent chemoradiotherapy (SKYSCRAPER-07): a randomised, phase III study. — Atezolizumab plus tiragolumab did not improve INV-PFS versus placebo (HR 0.82, 95% CI 0.65-1.03; p=0.0947)
- Liver resection after atezolizumab and bevacizumab versus maintenance therapy for locally advanced hepatocellular carcinoma (TALENTOP): a multicentre, open-label, randomised, phase 3 trial. — Median time to treatment failure 20.4 months with surgery versus 11.8 months with maintenance (HR 0.60, 95% CI 0.39-0.91; p=0.015)
- Durvalumab and tremelimumab, with or without lenvatinib, combined with transarterial chemoembolisation in participants with embolisation-eligible hepatocellular carcinoma (EMERALD-3): a global, randomised, open-label, sponsor-blinded, phase 3 study. — Median PFS 13.0 months for STRIDE plus lenvatinib plus TACE versus 9.8 months for TACE (HR 0.70; p=0.0007)
- Chemoradiotherapy versus short-course radiotherapy for response-adapted organ preservation in early-stage and intermediate-stage rectal cancer (STAR-TREC): 12-month results of an international, multicentre, open-label, parallel-group, randomised, phase 2/3 trial. — 12-month TME-free survival 78.5% with LCCRT versus 60.6% with SCRT (HR 1.90, 95% CI 1.29-2.81)
- Long-Term Survival Outcomes of Modified-FOLFOXIRI Plus Cetuximab Versus Bevacizumab in RAS/BRAF Wild-Type Metastatic Colorectal Cancer: Final Analysis of the DEEPER Trial. — In RAS/BRAF wild-type left-sided tumors median PFS 14.8 versus 11.9 months (HR 0.71; P = .029)
🐦 Twitter / 🦋 Bluesky
- NEST phase 2 published: neoadjuvant botensilimab plus balstilimab drives major pathologic responses in mismatch repair proficient colon cancer — In 24 patients with localized colorectal cancer treated with botensilimab plus balstilimab before surgery, 60% had major responses
- FDA approves daraxonrasib for previously treated metastatic pancreatic adenocarcinoma, and clinicians debate the RAS-agnostic label, first-line sequencing and cost — Approval was based on RASolute 302, where daraxonrasib gave OS 13.2 versus 6.7 months against chemotherapy in second-line metastatic pancreatic cancer (HR 0.4)
- TALENTOP in the Lancet: liver resection after atezolizumab plus bevacizumab extends time to treatment failure in advanced HCC with macrovascular invasion — Median time to treatment failure was 20.4 versus 11.8 months with surgery versus maintenance (HR 0.60, 95% CI 0.39-0.91, p=0.015)
- FDA approves zanidatamab-based regimens for first-line HER2-positive gastroesophageal adenocarcinoma, replacing a 15-year trastuzumab backbone — Approval based on HERIZON-GEA-01 includes a median overall survival of 26.4 months
- DEEPER final analysis: cetuximab beats bevacizumab with triplet chemotherapy only in RAS/BRAF wild-type left-sided metastatic colorectal cancer — In left-sided tumors median PFS was 14.8 months with cetuximab versus 11.9 months with bevacizumab (P = .029)
Full details below ↓
📄 What's Being Published
Atezolizumab with or without tiragolumab in unresectable esophageal squamous cell carcinoma following definitive concurrent chemoradiotherapy (SKYSCRAPER-07): a randomised, phase III study. — Xu R-H et al., Ann Oncol
In SKYSCRAPER-07, atezolizumab plus tiragolumab did not statistically improve investigator-assessed PFS versus placebo (HR 0.82, 95% CI 0.65–1.03; p=0.0947). However, atezolizumab plus placebo versus placebo significantly improved OS (HR 0.69, 95% CI 0.52–0.91; descriptive p=0.0085) as well as INV-PFS (HR 0.74, 95% CI 0.58–0.93).
Clinical bottom line: No new data since prior coverage — atezolizumab consolidation after definitive chemoradiotherapy improves survival in unresectable esophageal squamous cell carcinoma, while adding tiragolumab adds toxicity without benefit.
Liver resection after atezolizumab and bevacizumab versus maintenance therapy for locally advanced hepatocellular carcinoma (TALENTOP): a multicentre, open-label, randomised, phase 3 trial. — Sun Hui-Chuan et al., Lancet
TALENTOP randomised responders to atezolizumab plus bevacizumab to liver resection or maintenance therapy: median time to treatment failure was 20.4 months in the surgery group versus 11.8 months in the maintenance therapy group (HR 0.60, 95% CI 0.39–0.91; p=0.015). Grade 3 or 4 treatment-related adverse events occurred in 32 (39%) of 83 patients in the surgery group and 21 (21%) of 100 in the maintenance therapy group.
Clinical bottom line: With the full Lancet paper now out and widely circulated, resectability should be re-assessed by the multidisciplinary team in advanced HCC responders to atezolizumab plus bevacizumab, accepting a near doubling of grade 3–4 toxicity.
Ifebemtinib plus garsorasib in previously treated metastatic colorectal cancer with KRASG12C mutation: a multicentre, randomised, phase 1b/2 trial. — Song Zhengbo et al., Lancet Oncol
In the randomised portion, the confirmed objective response rate was 38.9% (95% CI 17.3–64.3) with the combination versus 16.7% (95% CI 3.6–41.4) with garsorasib alone (between-group difference 22.2%, 95% CI −7.7 to 49.1; one-sided p=0.068). In the single-arm part, the confirmed objective response rate was 46.7% (95% CI 21.3–73.4).
Clinical bottom line: Adding a focal adhesion kinase inhibitor to garsorasib roughly doubles response rate in KRAS G12C-mutated metastatic colorectal cancer, but the randomised comparison was not statistically significant, so this combination stays investigational.
On-demand transarterial chemoembolisation combined with atezolizumab and bevacizumab in patients with untreated hepatocellular carcinoma (TALENTACE): a multicentre, randomised, open-label, phase 3 trial. — Kudo Masatoshi et al., Lancet Gastroenterol Hepatol
Median TACE-PFS was 11.30 months (95% CI 7.52–15.01) with TACE plus atezolizumab and bevacizumab versus 7.03 months (95% CI 5.32–8.41) with TACE alone (HR 0.71 [95% CI 0.55–0.92]; p=0.0089). At the first interim analysis, median overall survival was 34.53 months in the combination group compared with 35.38 months in the TACE alone group (HR 0.96 [99.62% CI 0.58–1.58]).
Clinical bottom line: Adding atezolizumab plus bevacizumab to on-demand TACE delays TACE failure but has shown no survival separation at the first interim analysis, so it should not yet displace TACE alone outside a trial.
Durvalumab and tremelimumab, with or without lenvatinib, combined with transarterial chemoembolisation in participants with embolisation-eligible hepatocellular carcinoma (EMERALD-3): a global, randomised, open-label, sponsor-blinded, phase 3 study. — Kudo Masatoshi et al., Lancet Oncol
Median progression-free survival was 13.0 months (95% CI 12.2–16.7) for STRIDE plus lenvatinib plus TACE versus 9.8 months (95% CI 8.0–11.4) for TACE (HR 0.70 [95% CI 0.57–0.86]; p=0.0007), but median overall survival was 39.5 months versus 34.7 months (HR 0.84 [95% CI 0.65–1.09]; p=0.18) with no significant separation. Serious adverse events occurred in 184 (64%) participants receiving STRIDE plus lenvatinib plus TACE versus 68 (23%) receiving TACE.
Clinical bottom line: EMERALD-3 makes a STRIDE-based regimen with TACE a real option in embolisation-eligible HCC, but the lenvatinib arm buys progression-free survival at a steep toxicity cost with no survival signal yet, so patient selection is the unresolved question.
Chemoradiotherapy versus short-course radiotherapy for response-adapted organ preservation in early-stage and intermediate-stage rectal cancer (STAR-TREC): 12-month results of an international, multicentre, open-label, parallel-group, randomised, phase 2/3 trial. — Bach Simon P et al., Lancet Oncol
Among 409 participants in the modified intention-to-treat population (163 allocated to long-course chemoradiotherapy [LCCRT], 168 to short-course radiotherapy [SCRT], and 78 to primary TME), 12-month TME-free survival was 78.5% (95% CI 72.4–85.1) with LCCRT and 60.6% (95% CI 53.6–68.4) with SCRT (HR 1.90 [95% CI 1.29–2.81]).
Clinical bottom line: For response-adapted organ preservation in mrT1–T3bN0 rectal cancer, long-course chemoradiotherapy should be the radiotherapy backbone rather than short-course radiotherapy, pending the 30-month endpoint.
Extended Follow-Up of Botensilimab Plus Balstilimab in an Expanded Cohort of Microsatellite-Stable Metastatic Colorectal Cancer Without Active Liver Metastases. — Schlechter Benjamin L et al., Clin Cancer Res
In 123 patients, ORR was 21% (95% CI, 14–29), median PFS was 4.0 months (95% CI, 2.8–4.1), and median OS was 21.2 months (95% CI, 16.2–23.8), with a 36-month OS of 33% (95% CI, 24–43). Efficacy was consistent in late-line-exposed patients (n=37; ORR 22% [95% CI, 10–38]; median OS 16.2 months [95% CI, 9.7–31.3]).
Clinical bottom line: Botensilimab plus balstilimab produces durable responses and a 21.2-month median overall survival in microsatellite-stable metastatic colorectal cancer without active liver metastases, defining that no-liver-metastasis population as the setting where checkpoint combinations deserve randomised testing.
Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment, and follow-up of patients with hepatocellular carcinoma. — Tan C K et al., ESMO Open
The ESMO HCC guidelines published in May 2025 were adapted in August 2025 according to previously established standard methodology to produce the Pan-Asian consensus guidelines for management of Asian patients with HCC. Voting was based on scientific evidence and was independent of current treatment practices, drug access restrictions, and reimbursement decisions in the different regions of Asia.
Clinical bottom line: The Pan-Asian adaptation harmonises HCC management across ten Asian oncology societies while explicitly flagging drug approval and reimbursement disparities as the practical limit on guideline adherence.
Ultrasensitive circulating tumor DNA analysis improves detection of molecular residual disease in locally advanced esophageal cancer. — Rhoades Justin et al., Clin Cancer Res
Among patients with recurrence and postoperative plasma available, 9 of 14 (64%) tested ctDNA-positive at their first postoperative sample. Notably, ctDNA was detected below the limit of detection for first-generation assays in 59% of all samples in which ctDNA was detected.
Clinical bottom line: No new data since prior coverage — molecular residual disease testing in locally advanced esophageal cancer requires part-per-million sensitivity, because most detectable ctDNA in this setting sits below first-generation assay limits.
EMB-01, an Anti-EGFR/c-MET Bispecific Antibody, in Patients with Heavily Pretreated Metastatic Colorectal Cancer From a Phase Ib/II, Open-Label, Multicenter Study. — Xu Ting et al., Clin Cancer Res
Among 48 metastatic colorectal cancer patients, the confirmed objective response rate was 12.5% (95% CI, 4.7–25.2%), with a median duration of response of 32.0 weeks (95% CI, 16.0 to not estimable). Grade ≥3 treatment-related adverse events occurred in 63.5% of patients, with rash (25.0%) and dermatitis acneiform (17.3%) most frequently reported.
Clinical bottom line: EMB-01 shows activity confined to the left-sided, RAS/RAF wild-type, late-line-naive subgroup at the price of substantial grade 3 skin toxicity, so any further development must prospectively select that population.
Neoadjuvant Botensilimab/Balstilimab for localized mismatch repair proficient and deficient colon cancer: Results of the NEST phase 2 clinical trial. — Shah Manish A et al., Clin Cancer Res
Twenty-four eligible patients (26 tumors; 22 pMMR, 4 dMMR) were enrolled, and neoadjuvant botensilimab plus balstilimab did not delay planned surgery in any patient. The major pathologic response rate was 41% (95% CI, 21%–64%) for pMMR and 100% (95% CI, 40%–100%) for dMMR colorectal cancer.
Clinical bottom line: A 41% major pathologic response rate in mismatch repair proficient colon cancer with no surgical delay is far beyond anything single-agent PD-1 blockade has achieved here and justifies the randomised phase III that follows.
Long-Term Survival Outcomes of Modified-FOLFOXIRI Plus Cetuximab Versus Bevacizumab in RAS/BRAF Wild-Type Metastatic Colorectal Cancer: Final Analysis of the DEEPER Trial. — Sunakawa Yu et al., J Clin Oncol
In patients with RAS/BRAF wild-type and left-sided tumors, median PFS was longer with cetuximab than with bevacizumab (14.8 vs 11.9 months; HR 0.71 [95% CI, 0.52–0.97]; P = .029). Median OS was 50.2 months for cetuximab and 40.2 months for bevacizumab (HR 0.74 [95% CI, 0.53–1.05]).
Clinical bottom line: With no difference in the per-protocol set, DEEPER's final analysis supports cetuximab over bevacizumab with triplet chemotherapy only in the RAS/BRAF wild-type left-sided subgroup, and that remains an exploratory signal rather than a mandate.
🗂 Every paper considered this week, including the ones that didn’t make it →
🗣️ What People Were Discussing This Week
How these are chosen: filtered for clinical relevance, grouped by the new development discussed, then ordered by engagement (bookmarks and reposts).
NEST phase 2 published: neoadjuvant botensilimab plus balstilimab drives major pathologic responses in mismatch repair proficient colon cancer
In 24 patients with localized colorectal cancer treated with botensilimab plus balstilimab before surgery, 60% had major responses; among the 22 pMMR/MSS tumors, the major pathologic response rate was 41%, pCR was 32%, and 59% had at least 50% tumor regression, with 88% pre-surgical ctDNA clearance and no recurrences at 32.2 and 23.5 months. Commentators note that chemotherapy yields pCR in only approximately 2–7% in this setting, placing the 41% major pathologic response rate in sharp relief. Extending the pre-surgical window from 4 to 8 weeks in NEST2 was associated with deepened pathologic responses that nearly doubled, and disease-free status has been maintained with NEST1 at approximately 32 months and NEST2 at approximately 24 months. The central debate is whether this major pathologic response rate is sufficient to move neoadjuvant dual checkpoint blockade into a randomised phase III using event-free survival rather than pathologic response as the primary endpoint.
Discussed by: @pashtoonkasi, @pashtoonkasi, @GIMedOnc, @Aiims1742, @mtmdphd, @MDmanishshah, @pashtoonkasi, @FernandoOnco
FDA approves daraxonrasib for previously treated metastatic pancreatic adenocarcinoma, and clinicians debate the RAS-agnostic label, first-line sequencing and cost
The FDA approved daraxonrasib for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or are not candidates for multiagent systemic therapy, based on RASolute 302, where daraxonrasib produced a median OS of 13.2 versus 6.7 months against chemotherapy (HR 0.4) in a 500-patient trial, an approval issued approximately 6.5 months ahead of schedule. A key tension is that the FDA label is RAS-status agnostic — given that RAS mutations are present in more than 90% of pancreatic adenocarcinoma — whereas ESMO restricted its guideline recommendation to RAS G12 mutations; a dissenting column argues the benefit may be overstated in RASolute 302 due to informative censoring, with 55 of 214 (26%) control patients having withdrawn or deteriorated on treatment. Skin toxicity is described as real, with management extrapolated from EGFR inhibitors, and clinicians are advised to follow lungs closely for pneumonitis; access and affordability have been raised as an immediate practical barrier. Clinicians question whether a patient fit for multiagent chemotherapy should proceed to daraxonrasib or chemotherapy first, and investigators note that RASolute-303 is now testing daraxonrasib as initial treatment for metastatic disease alongside next-generation RAS inhibitors and degraders.
Discussed by: @VivekSubbiah, @Melanoma_doctor, @OncBrothers, @EladSharonMD, @EladSharonMD, @stolaney1, @stolaney1, @VivekSubbiah, @VivekSubbiah, @CathyEngMD, @rcarvalhoonco, @jgong15, @jgong15, @CentralParkWMD, @PearlF, @GIMedOnc, @ronanhsieh, @DrJashDatta
TALENTOP in the Lancet: liver resection after atezolizumab plus bevacizumab extends time to treatment failure in advanced HCC with macrovascular invasion
TALENTOP reported a median time to treatment failure of 20.4 versus 11.8 months with surgery versus maintenance (HR 0.60, 95% CI 0.39–0.91; p=0.015), with R0 resection in 93% and pCR in 28% among resected patients. Only 201 of 489 patients (41%) entered randomisation, making the selection of responders a central issue in interpreting the result; grade 3–4 treatment-related adverse events were 39% versus 21%, with two treatment-related deaths in the surgery arm. The trial is read by specialists as supporting neoadjuvant concepts and response-adapted treatment strategies in HCC. The open question is which responders should actually be taken to resection given a doubling of grade 3–4 toxicity and an endpoint that is not overall survival.
Discussed by: @ArndtVogel, @jgong15, @ChandrakanthMv, @ronanhsieh, @OncoAlert, @OncoAlert
FDA approves zanidatamab-based regimens for first-line HER2-positive gastroesophageal adenocarcinoma, replacing a 15-year trastuzumab backbone
Based on the phase 3 HERIZON-GEA-01 trial, zanidatamab plus tislelizumab plus chemotherapy produced a PFS of 12.4 versus 8.1 months (HR 0.63) and an OS of 26.4 versus 19.2 months (HR 0.72) against trastuzumab plus chemotherapy, with no PD-L1 restriction on the tislelizumab-containing regimen. The label distinguishes IHC 3+ tumors, where zanidatamab plus chemotherapy can be used with or without tislelizumab, from IHC 2+/ISH+ tumors, where tislelizumab is required. A practical safety concern is diarrhea: any-grade 83%, grade ≥3 approximately 25%, with loperamide prophylaxis mandated in cycle 1. The key caveat is that HERIZON-GEA-01 used trastuzumab plus chemotherapy as its control, with no direct head-to-head against trastuzumab plus pembrolizumab, leaving the question of default regimen selection unresolved.
Discussed by: @GIMedOnc, @ronanhsieh, @sonbol_bassam, @rutikamehtaMD, @Dr_ElvinaA, @OncBrothers, @kazuki_nozawa
DEEPER final analysis: cetuximab beats bevacizumab with triplet chemotherapy only in RAS/BRAF wild-type left-sided metastatic colorectal cancer
The final DEEPER analysis found that in left-sided RAS/BRAF wild-type tumors, median PFS was 14.8 months with cetuximab versus 11.9 months with bevacizumab (P = .029), and median OS was 50.2 months with cetuximab versus 40.2 months with bevacizumab. This left-sided signal sits alongside the pre-existing guideline position that already directs RAS/BRAF wild-type left-sided tumors to doublet chemotherapy plus anti-EGFR. The unresolved debate is whether DEEPER's left-sided survival gap changes first-line practice when the per-protocol analysis showed no PFS or OS difference.
Discussed by: @OncoAlert, @ChandrakanthMv, @ChandrakanthMv
HARMONi-GI1: ivonescimab plus chemotherapy beats durvalumab plus chemotherapy on overall survival in first-line advanced biliary tract cancer
The phase 3 HARMONi-GI1 trial, a single-region trial conducted in China, reported a statistically significant and clinically meaningful improvement in OS with first-line ivonescimab plus chemotherapy versus durvalumab plus chemotherapy in advanced biliary tract cancer. Earlier ivonescimab plus gemcitabine/cisplatin data in advanced biliary tract cancer had reported an ORR of 66.7%, DCR of 100%, median OS of 16.8 months, and median PFS of 8.5 months, with high MAP2K7 expression linked to resistance. The central question for oncologists outside China is whether a single-region phase 3 win for this PD-1 × VEGF bispecific is sufficient to change the first-line biliary tract standard more broadly.
Discussed by: @BalazsHalmosMD, @CathyEngMD, @hongjaechon, @EladSharonMD, @OncoAlert
BioNTech halts its ctDNA-positive resected colorectal cancer vaccine trial for futility
BioNTech terminated BNT122-01, the phase 2 of autogene cevumeran in ctDNA-positive resected colorectal cancer, after the DSMB found a numerical imbalance in overall survival; the failure is characterised as monotherapy in a cold tumor rather than an indictment of the neoantigen vaccine platform. Other mRNA cancer vaccine programs continue, and commentators contrast the colorectal result with Moderna's melanoma data as a reminder that evidence belongs to the population studied. The debate is whether the BNT122-01 futility stop indicts individualised neoantigen vaccines in ctDNA-positive colorectal cancer specifically, or only vaccine monotherapy in a cold tumor.
Discussed by: @OncoAlert, @MorningGlorySci
🔥 Top Ranked Tweets
OncoAlert @OncoAlert
RT @DrRishabhOnco: 🚨 TALENTOP: Surgery after immunotherapy may reshape locally advanced HCC
In patients with HCC + macrovascular invasion, no extrahepatic metastasis, who achieved PR/SD after atezolizumab + bevacizumab and became resectable:
📌 Phase III TALENTOP
201 patients randomized:
• Liver resection → atezo/bev × 12 months
vs
• Continue atezo/bev maintenance
📊 Primary endpoint: Time to treatment failure
20.4 vs 11.8 months
HR 0.60 (95% CI 0.39–0.91)
p=0.015
Nearly 40% reduction in treatment failure with the surgery strategy.
Among those actually resected:
🔹 R0 resection: 93%
🔹 Pathological CR: 28%
⚠️ The price:
Grade 3–4 TRAEs 39% vs 21%
Serious TRAEs 23% vs 7%
Two treatment-related deaths occurred in the surgery arm.
💡 Why it matters
This is the first randomized phase III evidence supporting conversion resection after systemic therapy in carefully selected advanced HCC responders.
⚠️ Limitations
China-only population, predominantly HBV-related disease, highly selected resectable patients, and OS remains immature.
🩺 Clinical verdict: IMPORTANT / POTENTIALLY PRACTICE CHANGING
Don’t operate on every responding advanced HCC. But after atezo/bev, resectability should now become an MDT question, not an afterthought.
#HCC #LiverCancer #Oncology @ASCO @oncoalert
🔖 15 ❤️ 31 🔁 15 👁 1,641
Arndt Vogel @ArndtVogel
Liver resection after atezolizumab and bevacizumab versus maintenance therapy for locally advanced HCC (TALENTOP): a multicentre phs 3 trial
@TheLancet
https://t.co/e2Zm4vbRdK
👉supports neoadjuvant concepts in HCC
👉response adopted treatment
@myESMO @EASLnews @ILCAnews https://t.co/rVFu9jPWUp
🔖 34 ❤️ 86 🔁 33 👁 4,532
Karamvir Yadav @K_Yadavir
🧬 ASCO Living Guideline 2026.1.2 is here.
Advanced gastroesophageal cancer is becoming increasingly biomarker-directed.
Key shift:
🔹 Test early: PD-L1, MSI/dMMR, CLDN18.2 & HER2
🔹 New HER2+ first-line evidence from HERIZON-GEA-01
🔹 Don’t overinterpret the PD-L1 <1 subgroup
#GastricCancer #Oncology #Immunotherapy @OpenEvidence @OncoDailyGI
🔖 17 ❤️ 24 🔁 9 👁 2,020
OncLive.com @OncLive
Updated @ASCO Living Guideline recommendations expand frontline therapy for HER2-positive gastroesophageal cancer to include zanidatamab-based regimens. #esocsm #oncology
https://t.co/jKcckkXStY
🔖 1 ❤️ 3 🔁 1 👁 1,200
Vivek Subbiah, MD @VivekSubbiah
🚨🚨🚨⭐️HUGE news & a MAJOR milestone in oncology‼️
👉🏼The FDA just approved the first targeted therapy for metastatic pancreatic cancer a breakthrough in precision oncology and a landmark step in making the BIG KRAS officially druggable ( beyond KRAS K12C) ❗️
$RVMD
👉🏼A new era in the fields battle against a devastating Emperor of all maladies. #precisionmedicine #KRAS
@OncoAlert @oncodaily @DavidHongMD @Aiims1742 @DrShubhamPant @GIcancerDoc @EileenMOReilly
https://t.co/p5ePQEJSLm
🔖 3 ❤️ 64 🔁 23 👁 12,674
Vivek Subbiah, MD @VivekSubbiah
RT @Aiims1742: Amazing news today, culmination of years of research & clinical trials in #PancreaticCancer.
The @RevMedicines approval for Rasonque (Daraxonrasib) will open many doors, including other inhibitors in this space & combinations. @OncoAlert @KRASKickers
https://t.co/07rvyKVQpy
🔖 11 ❤️ 201 🔁 75 👁 19,090
Vivek Subbiah, MD @VivekSubbiah
RT @VivekSubbiah: 🚨🚨🚨⭐️HUGE news & a MAJOR milestone in oncology‼️
👉🏼The FDA just approved the first targeted therapy for metastatic pancreatic cancer a breakthrough in precision oncology and a landmark step in making the BIG KRAS officially druggable ( beyond KRAS K12C) ❗️
$RVMD
👉🏼A new era in the fields battle against a devastating Emperor of all maladies. #precisionmedicine #KRAS
@OncoAlert @oncodaily @DavidHongMD @Aiims1742 @DrShubhamPant @GIcancerDoc @EileenMOReilly
https://t.co/p5ePQEJSLm
🔖 3 ❤️ 64 🔁 23 👁 12,674
Vivek Subbiah, MD @VivekSubbiah
⭐️Really loving the wording in the daraxonrasib FDA approval. Clear autonomy for physicians, centered on patient needs.
👉🏼“The approval is for the treatment of adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or are not candidates for multiagent systemic therapy”
👉🏼This is how oncology should move forward @OncoAlert @matthewherper @oncodaily @OpenEvidence @FDA @FDAOncology @FDAMedia @DrSamuelBHume
[Quoting @VivekSubbiah: 🚨🚨🚨⭐️HUGE news & a MAJOR milestone in oncology‼️
👉🏼The FDA just approved the first targeted therapy for metastatic pancreatic cancer a breakthrough in precision oncology and a landmark step in making the BIG KRAS officially druggable ( beyond KRAS K12C) ❗️
$RVMD
👉🏼A new era in the fields battle against a devastating Emperor of all maladies. #precisionmedicine #KRAS
@OncoAlert @oncodaily @DavidHongMD @Aiims1742 @DrShubhamPant @GIcancerDoc @EileenMOReilly
https://t.co/p5ePQEJSLm]
🔖 8 ❤️ 70 🔁 18 👁 10,681
Oriol Mirallas MD @DrMirallas
🚀 @FDA just approved #Daraxonrasib for #PancreaticCancer
👏🏽 Great news for patients with #PDAC with #KRAS G12, G13 or Q61
@_SEOM @myESMO @ASCO @UTMDAnderson @DavidHongMD @GarridoLagunaMD @EileenMOReilly @DrShubhamPant
Full approval 👇🏽
https://t.co/4pUuqHzlRn
🔖 0 ❤️ 3 🔁 1 👁 194
Vivek Subbiah, MD @VivekSubbiah
RT @ASCO: 💡Groundbreaking research presented at #ASCO26 continues to make headlines with the approval of daraxonrasib for some patients with metastatic pancreatic cancer #pancan
🔖 0 ❤️ 19 🔁 8 👁 4,803
Vivek Subbiah, MD @VivekSubbiah
RT @Aiims1742: 🔥🔥🔥
DARAXONRASIB APPROVED FOR METASTATIC #PancreaticCancer
https://t.co/07rvyKVQpy
🔖 4 ❤️ 146 🔁 48 👁 9,577
Vivek Subbiah, MD @VivekSubbiah
RT @DrChoueiri: JUST IN: @FDA approves RAS inhibitor Daraxonrasib in pancreatic cancer. Our @DanaFarber own Dr Brian Wolpin presented the data @ASCO 2026 annual meeting ! https://t.co/fanXU3yIgK
🔖 1 ❤️ 64 🔁 17 👁 2,752
Dr. Cathy Eng @CathyEngMD
RT @Aiims1742: 🔥🔥🔥
DARAXONRASIB APPROVED FOR METASTATIC #PancreaticCancer
https://t.co/07rvyKVQpy
🔖 4 ❤️ 146 🔁 48 👁 9,581
Vivek Subbiah, MD @VivekSubbiah
F.D.A. Approves the Drug Daraxonrasib That’s Poised to Transform Pancreatic Cancer - The New York Times https://t.co/3Ey5vWAUvW
🔖 1 ❤️ 20 🔁 8 👁 1,281
OncoAlert @OncoAlert
The FDA 🇺🇸 approved daraxonrasib, a first-in-class RAS inhibitor, for adults with metastatic pancreatic adenocarcinoma who have received prior systemic therapy or cannot receive multiagent treatment. Taken daily, the drug targets RAS proteins that drive tumor growth.
✅️ The approval, issued ahead of schedule, provides a new treatment option for a cancer with limited therapies and poor outcomes. #PancreaticCancer
https://t.co/Iv2XGawyFI
@CathyEngMD
@BenWestphalen
@graokane
@NiuSanford
@AndresC27622123
@GillSharlene
@pashtoonkasi
@DrVilmaPBarcia
@Erman_Akkus
@GIMedOnc
@UOzkerim
@MarioBalsaMD
@p_ciracimd
@DraMartinezLago
@DaisukeKotani
@Aiims1742
@ARosen380
@realbowtiedoc
@KoheiShitara
@MarioBalsaMD
@realbowtiedoc
@p_ciracimd
@c_eng1
@sharlenegill
@alicat380
@erman_akkus__
@ninan1230
@shitarakohei
🔖 1 ❤️ 32 🔁 21 👁 8,233
Prepared by Rafael Santana-Davila, M.D. Questions or feedback? Just reply to this email.
Disclaimer: This digest is AI-generated. Content may contain errors -- always verify with original sources.
Know a colleague who would find this useful? Just forward them this email.